How Biomarkers Might Assist Information Kidney Cancer Therapy Earlier

At the 2025 Kidney Cancer Research Summit, Dr. Wenxin (Vincent) Xu sat down for an interview with CURE, by which, he mentioned the advantage of utilizing biomarkers to information remedy for renal cell carcinoma (a sort of kidney most cancers).

“If you [are able] to know at [ahead of time] that your treatment is not going well, those patients might do much better if you’re able to switch tracks early,” Xu emphasised within the interview.

During the dialog, he aimed to clarify to sufferers what KIM-1 is, and the way biomarkers like this can be utilized as a possible therapeutic goal to information kidney most cancers remedy extra exactly.

Xu is a doctor, medical oncologist and scientific trial investigator within the Lank Center Genitourinary Oncology at Dana-Farber Cancer Institute, in addition to an assistant professor of medication at Harvard Medical School, each positioned in Boston.

Transcript

How might KIM-1 be used to information kidney most cancers remedy extra exactly sooner or later?

There are some ways we might think about utilizing a blood take a look at for kidney most cancers, and what I’m going to debate will not be the one ones. Some of the plain methods this might be useful are, for instance, we all know that adjuvant immunotherapy after surgical procedure improves affected person survival. But whenever you actually break it down, out of all of the sufferers you are treating with adjuvant immunotherapy, solely 8% are sufferers who’re cured and wouldn’t have already been cured by the surgical procedure.

It’s a small variety of sufferers you are benefiting by treating a big quantity. Hopefully, when you’ve got a extra exact biomarker, we will slim that down and keep away from giving additional remedy to sufferers who do not want it, and maybe additionally determine which sufferers are at a very excessive danger and provides extra remedy to forestall recurrence in these sufferers. So that is simply one among some ways a blood take a look at might be helpful.

Another means, for instance, is that if a affected person has metastatic kidney most cancers and so they’re being handled with immunotherapy. You can think about that that affected person would possibly need to know earlier — earlier than the standard 12-week scan — whether or not the remedy is working or not. Because in the event you might know at three weeks as an alternative of 12 weeks that your remedy is basically not going effectively, these sufferers would possibly do significantly better in the event you’re in a position to swap tracks early.

This piece displays the writer’s private expertise and perspective. For medical recommendation, please seek the advice of your well being care supplier.

For extra information on most cancers updates, analysis and schooling, don’t forget to subscribe to CURE®’s newsletters here.